Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 41, Issue 3, 2016, Pages 231-238

  Choi, Jin Seok ^a   Choi, In ^b   Choi, Dong Hyun ^b  

^a Ajou University   (South Korea)

^b Chosun University   (South Korea)

Author keywords

Bioavailability; CYP3A4; Dehydronifedipine; Nifedipine; P gp; Pharmacokinetics; Pioglitazone; Rats

Indexed keywords

CYTOCHROME P450 3A4; DEHYDRONIFEDIPINE; DRUG METABOLITE; MULTIDRUG RESISTANCE PROTEIN; NIFEDIPINE; PIOGLITAZONE; RHODAMINE 123; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 3A; CYTOCHROME P450 3A INHIBITOR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; IC50; LIVER; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROTEIN EXPRESSION; RAT; SMALL INTESTINE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; ANIMAL; BIOAVAILABILITY; DOSE RESPONSE; DRUG INTERACTION; MALE; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; NIFEDIPINE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES;

EID: 84969802901     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-014-0249-y     Document Type: Article

References (38)

1. Benet LZ, Cummins CL, Wu CY (2003) Transporter–enzyme interactions: implications for predicting drug–drug interactions from in vitro data. Curr Drug Metab 4:393–398
2. Blackshear JL, Orlandi C, Williams GH, Hollenberg NK (1986) The renal response to diltiazem and nifedipine: comparison with nitroprusside. J Cardiovasc Pharmacol 8:37–43
3. Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, Walther B (2000) Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131–1152
4. Chilcott J, Tappenden P, Jones ML, Wight JP (2001) A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 23:1792–1823
5. Choi DH, Li C, Choi JS (2009) Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. Eur J Drug Metab Pharmacokinet 34:163–168
6. Choi JS, Choi JS, Choi DH (2014) Effects of licocharcone A on the bioavailability and pharmacokinetics of nifedipine in rats: possible role of intestinal CYP3A4 and P-gp inhibition by licochalcone A. Biopharm Drug Dispos 35:382–390
7. Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at bloodbrain barrier sites. Proc Natl Acad Sci 86:695–698
8. Crespi CL, Miller VP, Penman BW (1997) Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248:188–190
9. Cummins CL, Jacobsen W, Benet LZ (2002) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300:1036–1045
10. Doherty MM, Charman WN (2002) The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 41:235–253
11. Dorababu M, Nishimura A, Prabha T, Naruhashi K, Sugioka N, Takada K, Shibata N (2009) Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. Biomed Pharmacother 63:697–702
12. Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic–pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41–57
13. Funaki T, Soons PA, Guengerich FP, Breimer DD (1989) In vivo oxidative cleavage of a pyridine-carboxylic acid ester metabolite of nifedipine. Biochem Pharmacol 38:4213–4216
14. Grundy JS, Kherani R, Foster RT (1994) Sensitive high-performance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection. J Chromatogr B Biomed Appl 654:146–151
15. Hamann SR, Piascik MT, McAllister RG Jr (1986) Aspects of the clinical pharmacology of nifedipine, a dihydropyridine calcium-entry antagonist. Biopharm Drug Dispos 7:1–10
16. Han CY, Cho KB, Choi HS, Han HK, Kang KW (2008) Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis 29:1837–1844
17. He F, Bi HC, Xie ZY, Zuo Z, Li JK, Li X, Zhao LZ, Chen X, Huang M (2007) Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: application to high-throughput inhibition screening of terpenoids. Rapid Commun Mass Spectrom 21:635–643
18. Hong SP, Yang JS, Han JY, Ha SI, Chung JW, Koh YY, Chang KS, Choi DH (2011) Effects of lovastatin on the pharmacokinetics of diltiazem and its metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. J Pharm Pharmacol 63:129–135
19. Kajosaari LI, Jaakkola T, Neuvonen PJ, Backman JT (2006) Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. Eur J Clin Pharmacol 62:217–223
20. Kelly PA, Wang H, Napoli KL, Kahan BD, Strobel HW (1999) Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur J Drug Metab Pharmacokinet 24:321–328
21. Kuroha M, Kayaba H, Kishimoto S, Khalil WF, Shimoda M, Kokue E (2002) Effect of oral ketoconazole on first-pass effect of nifedipine after oral administration in dogs. J Pharm Sci 91:868–873
22. Leveque D, Jehl F (1995) P-glycoprotein and pharmacokinetics. Anticancer Res 15:231–336
23. Lewis DFV (1996) Cytochrome P450. Substrate specificity and metabolism. In: Cytochromes P450. Structure, function, and mechanism. Taylor & Francis, Bristol, p 123
24. Lin JH, Chiba M, Baillie TA (1999) Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135–158
25. 10. J Health Sci 56:310–320
26. Relling MV (1996) Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther Drug Monit 18:350–356
27. Rendic S, Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413–580
28. Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, Gilbert D, LeCluyse EL, Sinz MW (2003) Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos 31:439–446
29. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423
30. Sorkin EM, Clissold SP, Brogden RN (1985) Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs 30:182–274
31. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, Mori S (1988) Tissue distribution of P-glycoprotein encoded by a multidrug resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 48:1926–1929
32. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci 84:7735–7738
33. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1989) Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 37:159–164
34. Wacher VJ, Wu CY, Benet LZ (1995) Overlapping substrate specificites and tissues distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129–134
35. Walsky RL, Gaman EA, Obach RS (2005) Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 45:68–78
36. Wang Y, Zou MJ, Zhao N, Ren JG, Zhou H, Cheng G (2011) Effect of diallyl trisulfide on the pharmacokinetics of nifedipine in rats. J Food Sci 76:30–34
37. Watkins PB (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4:171–184
38. Yang SH, Choi JS, Choi DH (2011) Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Pharmacology 88:1–9